Radiation dosimetry and biodistribution of 99mTc-ethylene dicysteine-deoxyglucose in patients with non-small-cell lung cancer

Naomi R. Schechter; William D. Erwin; David J. Yang; E. Edmund Kim; Reginald F. Munden; Kenneth Forster; Lina C. Taing; James D. Cox; Homer A. MacApinlac; Donald A. Podoloff

doi:10.1007/s00259-009-1135-8

Radiation dosimetry and biodistribution of ^99mTc-ethylene dicysteine-deoxyglucose in patients with non-small-cell lung cancer

Naomi R. Schechter, William D. Erwin, David J. Yang, E. Edmund Kim, Reginald F. Munden, Kenneth Forster, Lina C. Taing, James D. Cox, Homer A. MacApinlac, Donald A. Podoloff

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

Purpose: To assess the radiation dosimetry and biodistribution of ^99mTc-labeled ethylene dicysteine deoxyglucose (^99mTc-EC- DG) in patients with non-small-cell lung cancer (NSCLC). Methods: Serial whole-body scans were acquired 0, 2, 4, 6 and 24 h after injection of ^99mTc-EC-DG (925 MBq) in seven NSCLC patients. Radiation dosimetry, blood clearance and SPECT imaging of the primary tumor were assessed. Results: The critical organ was the bladder wall, with average radiation absorbed dose over all seven patients of 2.47×10^-2 mGy/MBq. The average effective dose equivalent and effective dose were 6.20×10^-3 mSv/MBq (6.89 mSv/1,110 MBq) and 5.90×10^-3 mSv/MBq (6.54 mSv/1,110 MBq), respectively. The primary tumor was visualized with SPECT in six patients. On final pathology, one patient had a granuloma, which did not enhance with ^99mTc-EC-DG. Conclusion: ^99mTc-EC-DG has acceptable dosimetric and biodistribution properties as a diagnostic tumor-imaging agent. Future studies are planned to evaluate its diagnostic potential.

Original language	English (US)
Pages (from-to)	1583-1591
Number of pages	9
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	36
Issue number	10
DOIs	https://doi.org/10.1007/s00259-009-1135-8
State	Published - 2009

Keywords

Deoxyglucose
EC-DG
Glucosamine
Lung cancer
SPECT

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1007/s00259-009-1135-8

Cite this

Schechter, N. R., Erwin, W. D., Yang, D. J., Kim, E. E., Munden, R. F., Forster, K., Taing, L. C., Cox, J. D., MacApinlac, H. A., & Podoloff, D. A. (2009). Radiation dosimetry and biodistribution of ^99mTc-ethylene dicysteine-deoxyglucose in patients with non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 36(10), 1583-1591. https://doi.org/10.1007/s00259-009-1135-8

Schechter, NR, Erwin, WD, Yang, DJ, Kim, EE, Munden, RF, Forster, K, Taing, LC, Cox, JD, MacApinlac, HA & Podoloff, DA 2009, 'Radiation dosimetry and biodistribution of ^99mTc-ethylene dicysteine-deoxyglucose in patients with non-small-cell lung cancer', European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 10, pp. 1583-1591. https://doi.org/10.1007/s00259-009-1135-8

@article{f2427413f2ee43678a3babe5da6bcd67,

title = "Radiation dosimetry and biodistribution of 99mTc-ethylene dicysteine-deoxyglucose in patients with non-small-cell lung cancer",

abstract = "Purpose: To assess the radiation dosimetry and biodistribution of 99mTc-labeled ethylene dicysteine deoxyglucose (99mTc-EC- DG) in patients with non-small-cell lung cancer (NSCLC). Methods: Serial whole-body scans were acquired 0, 2, 4, 6 and 24 h after injection of 99mTc-EC-DG (925 MBq) in seven NSCLC patients. Radiation dosimetry, blood clearance and SPECT imaging of the primary tumor were assessed. Results: The critical organ was the bladder wall, with average radiation absorbed dose over all seven patients of 2.47×10-2 mGy/MBq. The average effective dose equivalent and effective dose were 6.20×10-3 mSv/MBq (6.89 mSv/1,110 MBq) and 5.90×10-3 mSv/MBq (6.54 mSv/1,110 MBq), respectively. The primary tumor was visualized with SPECT in six patients. On final pathology, one patient had a granuloma, which did not enhance with 99mTc-EC-DG. Conclusion: 99mTc-EC-DG has acceptable dosimetric and biodistribution properties as a diagnostic tumor-imaging agent. Future studies are planned to evaluate its diagnostic potential.",

keywords = "Deoxyglucose, EC-DG, Glucosamine, Lung cancer, SPECT",

author = "Schechter, {Naomi R.} and Erwin, {William D.} and Yang, {David J.} and Kim, {E. Edmund} and Munden, {Reginald F.} and Kenneth Forster and Taing, {Lina C.} and Cox, {James D.} and MacApinlac, {Homer A.} and Podoloff, {Donald A.}",

year = "2009",

doi = "10.1007/s00259-009-1135-8",

language = "English (US)",

volume = "36",

pages = "1583--1591",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer Verlag",

number = "10",

}

TY - JOUR

T1 - Radiation dosimetry and biodistribution of 99mTc-ethylene dicysteine-deoxyglucose in patients with non-small-cell lung cancer

AU - Schechter, Naomi R.

AU - Erwin, William D.

AU - Yang, David J.

AU - Kim, E. Edmund

AU - Munden, Reginald F.

AU - Forster, Kenneth

AU - Taing, Lina C.

AU - Cox, James D.

AU - MacApinlac, Homer A.

AU - Podoloff, Donald A.

PY - 2009

Y1 - 2009

N2 - Purpose: To assess the radiation dosimetry and biodistribution of 99mTc-labeled ethylene dicysteine deoxyglucose (99mTc-EC- DG) in patients with non-small-cell lung cancer (NSCLC). Methods: Serial whole-body scans were acquired 0, 2, 4, 6 and 24 h after injection of 99mTc-EC-DG (925 MBq) in seven NSCLC patients. Radiation dosimetry, blood clearance and SPECT imaging of the primary tumor were assessed. Results: The critical organ was the bladder wall, with average radiation absorbed dose over all seven patients of 2.47×10-2 mGy/MBq. The average effective dose equivalent and effective dose were 6.20×10-3 mSv/MBq (6.89 mSv/1,110 MBq) and 5.90×10-3 mSv/MBq (6.54 mSv/1,110 MBq), respectively. The primary tumor was visualized with SPECT in six patients. On final pathology, one patient had a granuloma, which did not enhance with 99mTc-EC-DG. Conclusion: 99mTc-EC-DG has acceptable dosimetric and biodistribution properties as a diagnostic tumor-imaging agent. Future studies are planned to evaluate its diagnostic potential.

AB - Purpose: To assess the radiation dosimetry and biodistribution of 99mTc-labeled ethylene dicysteine deoxyglucose (99mTc-EC- DG) in patients with non-small-cell lung cancer (NSCLC). Methods: Serial whole-body scans were acquired 0, 2, 4, 6 and 24 h after injection of 99mTc-EC-DG (925 MBq) in seven NSCLC patients. Radiation dosimetry, blood clearance and SPECT imaging of the primary tumor were assessed. Results: The critical organ was the bladder wall, with average radiation absorbed dose over all seven patients of 2.47×10-2 mGy/MBq. The average effective dose equivalent and effective dose were 6.20×10-3 mSv/MBq (6.89 mSv/1,110 MBq) and 5.90×10-3 mSv/MBq (6.54 mSv/1,110 MBq), respectively. The primary tumor was visualized with SPECT in six patients. On final pathology, one patient had a granuloma, which did not enhance with 99mTc-EC-DG. Conclusion: 99mTc-EC-DG has acceptable dosimetric and biodistribution properties as a diagnostic tumor-imaging agent. Future studies are planned to evaluate its diagnostic potential.

KW - Deoxyglucose

KW - EC-DG

KW - Glucosamine

KW - Lung cancer

KW - SPECT

UR - http://www.scopus.com/inward/record.url?scp=70350528643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350528643&partnerID=8YFLogxK

U2 - 10.1007/s00259-009-1135-8

DO - 10.1007/s00259-009-1135-8

M3 - Article

C2 - 19396440

AN - SCOPUS:70350528643

SN - 1619-7070

VL - 36

SP - 1583

EP - 1591

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 10

ER -